Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Cadwalader achieved a significant victory on behalf of the former directors of Salix Pharmaceuticals, Ltd. today when the Delaware Supreme Court rejected plaintiffs’ appeal of the Court of Chancery’s dismissal of plaintiffs’ complaint. In the complaint, plaintiffs had alleged claims for breach of fiduciary duties in connection with Salix’s acquisition by Valeant Pharmaceuticals International Inc. (NYSE: VRX) for $13.1 billion on April 1, 2015. https://www.cadwalader.com/news/news-release/cadwalader-achieves-delaware-supreme-court-victory-in-merger-challenge